Soft-Tissue Sarcoma and Sarcoma Subtypes
Clinical research at Institut Bergonie is strongly centered on soft-tissue sarcoma, including leiomyosarcoma, undifferentiated pleomorphic sarcoma, and resectable or advanced disease. The portfolio also includes osteosarcoma and Ewing sarcoma, with interest in both localized and metastatic settings.
- Advanced soft-tissue sarcoma
- Leiomyosarcoma
- Undifferentiated pleomorphic sarcoma
- Osteosarcoma and Ewing sarcoma
Research activity spans neoadjuvant, peri-operative, and metastatic sarcoma care, with attention to surgical disease, recurrence risk, and progression control.
Immuno-Oncology and Tumor Microenvironment
The sponsor is actively involved in immunotherapy for solid tumors, with studies focused on PD-1, PD-L1, and CTLA-4-related pathways, as well as combinations involving immune modulation. A recurring theme is the role of tertiary lymphoid structures and immune signatures in treatment response.
- PD-1 and PD-L1 blockade
- Immune checkpoint inhibition
- Tertiary lymphoid structures (TLS)
- Tumor microenvironment signatures
These investigations extend across solid tumors and emphasize immune-sensitive disease subsets, particularly in sarcoma and other advanced malignancies.
Advanced Solid Tumors and Metastatic Disease
Institut Bergonie also supports research in metastatic solid tumors and locally advanced unresectable cancer, including non-small cell lung cancer, colorectal cancer, pancreatic cancer, biliary tract cancer, triple negative breast cancer, and urothelial cancer.
- Non-small cell lung cancer
- Colorectal cancer
- Pancreatic cancer
- Triple negative breast cancer
Its clinical portfolio includes disease control and progression-focused research in heavily pretreated and biomarker-defined solid tumor populations.
Genitourinary Oncology and Prostate Cancer
The sponsor has a clear interest in prostate cancer, including intermediate unfavorable risk disease and metastatic castration-resistant prostate cancer. Research also touches on neuroendocrine prostate cancer within broader solid tumor programs.
- Intermediate unfavorable risk prostate cancer
- Metastatic castration-resistant prostate cancer
- Neuroendocrine prostate cancer
- Radiotherapy-associated treatment strategies
These studies reflect a focus on disease control in both localized and advanced genitourinary malignancies.
Targeted Therapy and Combination Oncology
Research activity includes targeted therapy and multi-agent combinations in advanced cancers, with attention to DNA damage response, epigenetic therapy, and anti-angiogenic approaches. The sponsor’s trial portfolio also explores combinations with chemotherapy and radiotherapy in difficult-to-treat tumors.
- Targeted therapy combinations
- DNA damage response pathways
- Epigenetic oncology
- Chemoradiation-based strategies
These programs are concentrated in advanced sarcoma and other metastatic solid tumors where treatment resistance remains a major clinical issue.
